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Pmpact of Valve Prosthesis-Patient
ismatch on Pulmonary Arterial
ressure After Mitral Valve Replacement
ingzhou Li, MD, PHD, Jean G. Dumesnil, MD, FACC, Patrick Mathieu, MD,
hilippe Pibarot, DVM, PHD, FACC
ainte-Foy, Quebec, Canada
OBJECTIVES We sought to determine the impact of valve prosthesis-patient mismatch (PPM) on
pulmonary arterial (PA) pressure after mitral valve replacement (MVR).
BACKGROUND Pulmonary arterial hypertension is a serious complication of mitral valve disease, and it is a
major risk factor for poor outcome after MVR. We hypothesized that valve PPM might be
a determinant of PA hypertension after MVR.
METHODS Systolic PA pressure was measured by Doppler echocardiography in 56 patients with normally
functioning mitral prosthetic valves. Mitral valve effective orifice area (EOA) was determined
by the continuity equation and indexed for body surface area.
RESULTS Thirty patients (54%) had PA hypertension defined as systolic PA pressure 40 mm Hg,
whereas 40 patients (71%) had PPM defined as an indexed EOA 1.2 cm2/m2. There was
a significant correlation (r  0.64) between systolic PA pressure and indexed EOA. The
average systolic PA pressure and prevalence of PA hypertension were 34  8 mm Hg and
19% in patients with no PPM versus 46  8 mm Hg and 68% in patients with PPM (p 
0.001). In multivariate analysis, the indexed EOA was by far the strongest predictor of systolic
PA pressure.
CONCLUSIONS Persistent PA hypertension is frequent after MVR and strongly associated with the presence
of PPM. The clinical implications of these findings are important given that PPM can largely
be avoided by using a simple prospective strategy at the time of operation. (J Am Coll
ublished by Elsevier Inc. doi:10.1016/j.jacc.2004.10.073Cardiol 2005;45:1034–40) © 2005 by the American College of Cardiology Foundation
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sulmonary arterial (PA) hypertension is a frequent and
erious complication of mitral valve diseases, and it is a
ajor risk factor for poor outcome after surgery for mitral
tenosis (1) or mitral regurgitation (2–4). Not surprisingly,
he impact of PA hypertension on morbidity and mortality
See page 1041
s highly dependent on its degree of severity. Severe PA
ypertension is associated with a high risk of perioperative
ortality (10% to 15%) in patients undergoing mitral valve
eplacement (MVR) as well as with increased mortality in
he long term (1–3). Nonetheless, mild PA hypertension is
ot necessarily benign because it is associated with signifi-
antly worse exercise capacity and higher morbidity and
ortality. Therefore, the normalization of PA pressure is a
rucial goal of MVR. Unfortunately, the regression of PA
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ccepted October 14, 2004.ypertension after operation varies extensively from one
atient to the other and is often incomplete (5,6).
The effective orifice area (EOA) of prosthetic valves used
or MVR is often too small in relation to body size, thus
ausing a mismatch between valve EOA and transvalvular
ow (7–10). As a consequence, normally functioning mitral
rostheses often have relatively high gradients that are
imilar to those found in patients with mild/moderate mitral
tenosis (6,9–11). Residual pressure gradients across mitral
rostheses may hinder or delay the regression of left atrial
nd PA hypertension (7–9). We, therefore, hypothesized
hat valve prosthesis-patient mismatch (PPM) might be an
mportant determinant of the persistence of PA hyperten-
ion after MVR. The main objective of this study was, thus,
o determine the impact of PPM on PA pressure after
VR.
ETHODS
atient population. We retrospectively analyzed the data
f patients with a mitral prosthesis who were consecutively
valuated by Doppler echocardiography at the Quebec
eart Institute between January 2003 and August 2003.
xclusion criteria were as follows: 1) evidence of overt
rosthetic valve dysfunction; 2) presence of 2 aortic
alve regurgitation and/or  mild aortic stenosis. Seventy-
wo patients met these eligibility criteria. Measurement of
ystolic PA pressure and/or mitral valve EOA could not be
btained in 14 of these patients. The study group was,
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April 5, 2005:1034–40 Impact of Mitral Prosthesis-Patient Mismatchherefore, composed of 56 patients with a mean age of 65
2 years and a median follow-up time of 43 months (range
to 102 months).
oppler-echocardiography. The systolic PA pressure was
alculated by adding the systolic right ventricular pressure
erived from the tricuspid regurgitation to the estimated
ight atrial pressure (12–14). Right atrial pressure was
stimated from the diameter and the degree of collapse of
he inferior vena cava during inspiration (14–16). Pulmo-
ary arterial hypertension was defined as a systolic PA
ressure 40 mm Hg (17).
Mitral valve EOA was determined by the continuity
quation using the stroke volume measured in the left
entricular outflow tract divided by the integral of the mitral
alve transprosthetic velocity during diastole; PPM was
efined as an indexed EOA 1.2 cm2/m2 as suggested in
revious studies (9,10), and, on this basis, the patients were
rbitrarily divided into two subgroups (i.e., those with no
PM and those with PPM).
Because atrioventricular compliance has been shown to
nfluence PA pressure in patients with mitral stenosis
18,19), we also elected to calculate this parameter, such as
uggested by Flaschkampf et al. (18,19). Indeed, these
uthors have presented analytical and numerical evidence
howing that net atrioventricular compliance (Cn), which is
he change in volume shift between left atrium and left
entricle during diastole divided by the change in transmi-
ral pressure gradient, can be determined noninvasively by
oppler-echocardiography using the following equation:
Cn 1,270 EOA/E-wave downslope [1]
hereby EOA is the mitral valve EOA determined by the
ontinuity equation in cm2, E-wave downslope is the mitral
elocity E-wave downslope measured in cm/s2, and the
esult is expressed in ml/mm Hg. Schwammenthal et al.
19) found that Cn as determined by this equation correlated
ell (r  0.79) with invasively determined values of the
ame parameter in patients with mitral stenosis. It should be
mphasized that Cn is theoretically affected by both atrial
nd ventricular chamber compliances but that these two
ariables cannot be measured individually by noninvasive
ethods. Nonetheless, the left atrium and left ventricle can
e seen as behaving like two capacitors in series, whereby
heir compliances combine to yield net atrioventricular
ompliance as follows:
Cn 1/Ca  1/Cv1 [2]
tatistical analysis. Differences between groups for preop-
Abbreviations and Acronyms
EOA  effective orifice area
MVR  mitral valve replacement
PA  pulmonary arterial
PPM  prosthesis-patient mismatchrative, operative, and postoperative variables were tested for 3tatistical significance by t test, chi-square test, or Fischer
xact test as appropriate. The Fischer exact test was used
nstead of the chi-square test when over 20% of the expected
alues in the contingency table were 5. Statistical analysis
f the association of variables was performed with the
earson correlation coefficient. A forward stepwise regres-
ion analysis was used to identify the independent determi-
ants of systolic PA pressure. Age and gender were forced
nto the multivariate model, whereas other variables were
ntered in the model when the p value was 0.1 in
nivariate analysis.
ESULTS
he patients demographic, preoperative, and operative
ata are presented in Table 1. For the whole group, the
redominant mitral valve lesion at the time of opera-
ion was mitral regurgitation in 43% of patients, mitral
tenosis in 41%, and mixed mitral valve disease in 16%,
hereas evidence of PA hypertension defined as a pre-
perative systolic PA pressure measured by Doppler-
chocardiography and/or catheter 40 mm Hg was present
n 67% of patients. A mechanical prosthesis was inserted in
4% of patients, whereas 16% received a bioprosthesis. The
odel of prosthetic valve was Standard St. Jude Medical
St. Jude Medical, Minneapolis, Minnesota) in 34 (61%)
atients; On-X (MCRI, Austin, Texas) in 5 (9%); Advan-
age (Medtronic) in 4 (7%); Medtronic-Hall (Medtronic) in
(7%); Mosaic (Medtronic) in 4 (7%); Hancock
Medtronic) in 2 (3.5%); Intact (Medtronic,) in 2 (3.5%);
nd homograft (Cryolife, Kennesaw, Georgia) in 1 (2%).
he mitral valve leaflets and chordae were totally or partially
posterior) preserved in 41% of patients. Concomitant
rocedures included left atrial appendage obliteration in
3%, Maze procedure in 9%, and coronary artery bypass
raft surgery in 16%. The proportion of small (27 mm)
alves was 52%, which is comparable with that reported in
revious recent series (20–24). There was no significant
ifference between patients having total, partial, or no
reservation of the valve leaflets and chordae with regard to
rosthesis size.
Based on an indexed EOA 1.2 cm2/m2, 40 of the 56
atients (71%) were classified as having PPM. In compar-
son to patients with no PPM, patients with PPM had a
ignificantly larger body surface area, a higher prevalence of
ystemic hypertension, and a higher proportion of smaller
rostheses; indeed, prosthesis size was 27 mm in 66% of
atients with PPM as compared to only 19% of patients
ithout PPM. The other preoperative and operative data
ere similar in both groups.
The postoperative Doppler-echocardiographic data are
resented in Table 2. The mean systolic PA pressure for the
hole group after operation was 42  10 mm Hg (range 22
o 61 mm Hg), whereas evidence of PA hypertension
efined as a systolic PA pressure 40 mm Hg was found in
0 of the 56 patients (54%).
I
E
l
P
p
s
a
2
w
t
g
H
h
c
T
A
E
E
E
E
E
M
I
P
M
N
S
P
S
1036 Li et al. JACC Vol. 45, No. 7, 2005
Impact of Mitral Prosthesis-Patient Mismatch April 5, 2005:1034–40mpact of PPM on PA pressure. As expected, mitral valve
OA and indexed mitral valve EOA were significantly
ower in patients with PPM as compared to patients with no
PM. The former patients also had significantly higher
eak and mean transvalvular pressure gradients, PA pres-
ure, and prevalence of PA hypertension, whereas their net
trioventricular compliance was significantly lower (Table
Table 1. Demographic, Preoperative, and Ope
Variables
All Patie
(n  56
Demographic data
Gender
Female 36 (64
Male 20 (36
Age (yrs) 65  1
Body surface area (m2) 1.72  0
Preoperative data
Predominant valvular dysfunction
Mitral stenosis 23 (41
Mitral regurgitation 24 (43
Mixed mitral valve dysfunction 9 (16
Coronary artery disease 12 (21
Diabetes 4 (7%
Systemic arterial hypertension 17 (30
Pulmonary arterial hypertension 32/48 (67
Operative data
Type of prosthesis
Mechanical prosthesis 47 (84
Bioprosthesis 9 (16
Prosthesis size (mm)
25 7 (13
27 22 (39
29 15 (27
31 10 (18
33 2 (4%
Total chordal preservation 5 (9%
Posterior chordal preservation 18 (32
Left atrial appendage obliteration 13 (23
Maze procedure 5 (9%
Coronary artery bypass graft 11 (20
*p value for the difference between PPM and no PPM grou
chi-square test. The prosthesis sizes have been regrouped int
to permit application of Fischer exact test.
PPM  prosthesis-patient mismatch.
able 2. Postoperative Doppler Echocardiographic Data
Variables
All P
(n 
trial fibrillation 22 (
nd-diastolic LV diameter (mm) 49 
nd-systolic LV diameter (mm) 34 
nd-diastolic interventricular septal thickness (mm) 10 
nd-diastolic LV posterior wall thickness (mm) 10 
nd-systolic LA diameter (mm) 51 
itral valve EOA (cm2) 1.8 
ndexed mitral valve EOA (cm2/m2) 1.1 
eak transmitral gradient (mm Hg) 11 
ean transmitral gradient (mm Hg) 4 
et atrioventricular compliance (ml/mm Hg) 4.1 
ystolic PA pressure (mm Hg) 42 
A hypertension (systolic PA pressure 40 mm Hg) 30 (ymbols as in Table 1.
EOA  effective orifice area; LA  left atrial; LV  left ventricular; PA  pulmonary). The indexed EOA (i.e., the degree of PPM) correlated
ell with postoperative PA pressures (r  0.64; Fig. 1) and
o a lesser extent with peak (r  0.50) and mean (r  0.46)
radients, and atrioventricular compliance (r  0.37).
ence, the average systolic PA pressure was significantly
igher (p  0.001) in patients with PPM (46  8 mm Hg)
ompared to patients with no PPM (34 8 mmHg) (Table
Data
No PPM
(n  16)
PPM
(n  40)
p
Value*
NS
10 (63%) 26 (65%)
6 (38%) 14 (35%)
63  14 66  11 NS
1.64  0.18 1.75  0.16 0.03
NS†
8 (47%) 15 (36%)
5 (33%) 19 (48%)
3 (20%) 6 (15%)
2 (13%) 10 (25%) NS†
1 (6%) 3 (8%) NS†
1 (6%) 16 (40%) 0.02†
11/16 (69%) 21/32 (66%) NS
NS†
14 (88%) 33 (83%)
2 (13%) 7 (18%)
* 0.001†
2 (13%) 5 (13%)
1 (6%) 21 (53%)
7 (44%) 8 (20%)
5 (31%) 5 (13%)
1 (6%) 1 (2%)
2 (13%) 3 (8%) NS
3 (19%) 13 (33%) NS
4 (25%) 9 (23%) NS†
2 (13%) 3 (8%) NS†
1 (6%) 10 (24%) NS†
ndicates when a Fischer exact test was used instead of the
categories (25 to 27 mm category vs. 29 to 33 mm category)
s No PPM
(n  16)
PPM
(n  40) p Value
7 (44%) 15 (38%) NS
50  7 49  7 NS
34  9 33  8 NS
10  1 10  2 NS
10  3 11  2 NS
52  14 50  10 NS
2.3  0.3 1.7  0.3 0.001
1.4  0.1 1.0  0.2 0.001
8  2 12  4 0.001
3  1 4  2 0.001
5.3  1.6 3.6  1.6 0.001
34  8 46  8 0.001
3 (19%) 27 (68%) 0.001†rative
nts
)
%)
%)
2
.17
%)
%)
%)
%)
)
%)
%)
%)
%)
%)
%)
%)
%)
)
)
%)
%)
)
%)
ps; †i
o twoatient
56)
39%)
7
9
2
2
11
0.4
0.3
4
2
1.7
10
54%)arterial; PPM  prosthesis-patient mismatch.
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April 5, 2005:1034–40 Impact of Mitral Prosthesis-Patient Mismatch). Likewise, the prevalence of persistent PA hypertension
fter MVR was 68% in patients with PPM versus 19% in
atients with no PPM (Fig. 2). An indexed mitral valve
OA1.2 cm2/m2 had a sensitivity of 68% and a specificity
f 81% to predict PA hypertension.
mpact of atrioventricular compliance on PA pressure. Sys-
olic PA pressure also correlated (r  0.53) with net
trioventricular compliance (Fig. 3). On average, patients
ith an atrioventricular compliance 4 ml/mm Hg had a
ignificantly higher (p  0.001) postoperative systolic PA
ressure (46  8 mm Hg) compared to those with compli-
nce 4.0 ml/mm Hg (36  8 mm Hg).
ndependent determinants of PA pressure. In multivari-
te analysis, the independent determinants of systolic PA
ressure were: indexed mitral valve EOA (p  0.001), net
trioventricular compliance (p  0.001), and mean trans-
alvular flow rate (p  0.04) (Table 3). Indexed EOA had
he most important contribution in the multivariate model
igure 1. Correlation between systolic pulmonary arterial (PA) pressure
nd indexed mitral valve effective orifice area. An indexed mitral valve
ffective orifice area 1.2 cm2/m2 afforded the best sensitivity and
pecificity for the prediction of PA hypertension defined as a systolic PA
ressure 40 mm Hg (thin lines).
igure 2. Prevalence of pulmonary arterial (PA) hypertension before and
fter mitral valve replacement in patients with prosthesis-patient mismatch
PPM) versus those with no PPM. Open bars  preoperative; solid bars
postoperative.
tollowed by atrioventricular compliance. Mean transvalvular
ow rate had a minimal contribution with borderline
ignificance. There was a weak (r  0.35, p  0.007)
orrelation between time to follow-up and postoperative PA
ressure in univariate analysis, but this variable was not a
ignificant independent predictor of PA pressure in multi-
ariate analysis.
In the subgroup of 48 patients in whom the preoperative
A pressure was available, this variable did not come out as
significant predictor of postoperative PA pressure in
ultivariate analysis, and the only significant predictors
ere the indexed MVA (R2  0.39, p  0.003) and the
et atrioventricular compliance (R2  0.08, p  0.01).
In Figure 4, the patients were separated into four sub-
roups depending on the presence of PPM and of low
triocompliance defined as being 4.0 ml/mm Hg. The
ystolic PA pressure and prevalence of PA hypertension
ere 33  9 mm Hg and 23% in patients (n  13) with no
PM and normal compliance, 34  2 mm Hg and 0% in
atients (n  3) with no PPM and low compliance, 40  5
m Hg and 36% in patients (n  11) with PPM and
ormal compliance, and 48  7 mm Hg and 79% in
atients (n  29) with PPM and low compliance.
igure 3. Correlation between systolic pulmonary arterial (PA) pressure
nd net atrioventricular compliance.
able 3. Independent Determinants of Postoperative Systolic
ulmonary Arterial Pressure
Variables
Standardized
Coefficient R2
p
Value
ge 0.14 — 0.11
ender 0.85 — 0.68
ndexed mitral valve EOA 0.52 0.41 0.001
et atrioventricular compliance 0.39 0.12 0.001
ean transvalvular flow rate 0.23 0.04 0.049
he R2 value represents the respective contribution of the variable to the variance of
he systolic pulmonary arterial pressure in the multivariate model.
EOA  effective orifice area.
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n increase in PA pressure can result from elevation of
ulmonary blood flow, pulmonary venous pressure, and/or
ascular resistance (25–27). The major consequence of PA
ypertension is right ventricular failure, which generally
esults from chronic pressure overload and associated vol-
me overload with the development of tricuspid regurgita-
ion (26); PA hypertension is an important risk factor for
orbidity and mortality in patients with cardiovascular
iseases (28–33). The clinical course of patients with PA
ypertension can be highly variable depending on the
nderlying disease. However, with the onset of right ven-
ricular failure, patient survival is generally limited to ap-
roximately six months (26); PA hypertension is frequently
30% to 70%) observed in patients with mitral valve disease
2–6,34). The passive elevation of PA pressure due to
levated left atrial pressure is the main mechanism leading
o PA hypertension in these patients. In addition to this
assive elevation of PA pressure, there is often a reactive
asoconstriction of the pulmonary arterioles that causes an
ncrease in pulmonary vascular resistance and, thus, contrib-
tes to the elevation of PA pressure. Moreover, in patients
ith longstanding disease, potentially irreversible structural
hanges may occur in the pulmonary vasculature.
Given that PA hypertension is quite prevalent in patients
ith severe mitral valve disease and that it is associated with
oor functional capacity and dismal prognosis (1–3,35),
ormalization of PA pressure, therefore, constitutes a cru-
ial goal of MVR. Successful surgical relief of the mechan-
cal cause of pulmonary venous hypertension generally
educes PA pressure and promotes regression of the revers-
ble components of pulmonary vascular changes (25,26).
nfortunately, the relief of the passive elevation of left atrial
ressure and, thus, of PA pressure is often incomplete, (5,6)
ikely due to the interaction of prosthesis- and/or patient-
elated factors. Zielinski et al. (5) reported PA pressure data
btained by catheterization before and one year after MVR.
n 14 patients with PA hypertension (defined as systolic PA
ressure 40 mm Hg) before operation, PA hypertension
igure 4. Systolic pulmonary arterial (PA) pressure according to valve
rosthesis-patient mismatch (PPM) and net atrioventricular compliance
Cn). Low Cn is defined as Cn 4.0 ml/mm Hg.as still present in seven patients (50%) one year after aperation. Furthermore, among the eight patients who had
ormal PA pressure before MVR, three (38%) developed
A hypertension after MVR. In addition, all patients except
wo had PA pressure 50 mm Hg when they were
ubmitted to mild exercise (25 W workload). Of the 56
atients included in the present study, 30 (54%) still had PA
ypertension after MVR.
mpact of PPM on PA pressure. Previous studies have
emonstrated that PPM is associated with inferior hemo-
ynamics, less regression of left ventricular hypertrophy,
ore cardiac events, and higher mortality rates after aortic
alve replacement (7,10,36–44). However, the hemody-
amic and clinical impact of PPM after MVR is relatively
nexplored (8–10). In the first published report of mitral
PM, Rahimtoola and Murphy (8) described the case of a
atient who remained symptomatic and had persistent PA
ypertension and progressive right-sided failure after MVR.
ccordingly, the major finding of the present study is that
PM is a strong risk factor for the persistence of PA
ypertension after MVR. Hence, the prevalence of PA
ypertension decreased from 69% to 19% after operation in
atients with no PPM, whereas it remained unchanged in
atients with PPM (66% before operation vs. 68% after
peration) (Fig. 2).
In patients with an aortic prosthesis, previous studies also
onsistently found a strong correlation between the indexed
OA and the postoperative transprosthetic gradients mea-
ured at rest or during exercise (36,40,45). However, as
eported in the present study as well as in the previous study
y Dumesnil et al. (9), the correlation between the indexed
OA and the mean transprosthetic pressure gradients is
ower in patients with mitral prostheses (r  0.50) than in
atients with aortic prostheses (r  0.75). In this context, it
hould be emphasized that the hemodynamics of the mitral
alve are much more sensitive to the chronotropic condi-
ions than that of the aortic valve. Indeed, for similar
ndexed EOA, the pressure gradients across the mitral valve
re highly influenced by the transvalvular flow rate, which is
ssentially determined by two factors: the diastolic filling
olume and the diastolic filling time. In turn, diastolic time
s highly dependent on heart rate. A change in heart rate has
much greater impact on the diastolic duration than on the
ystolic duration. This difference may contribute to the
xplanation of the lower correlation between indexed EOA
nd pressure gradients that is observed in mitral prostheses.
n this context, it is also interesting to note that the indexed
itral EOA correlated better with systolic PA pressure than
ith transprosthetic pressure gradients; this finding is con-
istent with the fact that PA pressure is probably less
nfluenced by chronotropic conditions than are pressure
radients.
trioventricular compliance, a physiological modulator
f PA pressure. Patients with chronic mitral valve disease
ften have an abnormally low atrial compliance due to left
trial remodeling and hypertrophy. In turn, a reduction in
trial compliance will necessarily result in a decrease in net
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April 5, 2005:1034–40 Impact of Mitral Prosthesis-Patient Mismatchtrioventricular compliance because, according to equation
, the latter is always lower than either of its two compo-
ents (i.e., left ventricular and left atrial compliances). In
atients with native mitral valve stenosis, Schwammenthal
t al. (19) demonstrated that atrioventricular compliance is
n important physiological modulator of left atrial and PA
ressures. In the context of MVR, it, however, becomes
vident that compliance is also influenced by PPM. This
bservation appears to be confirmed by the results of
nivariate and multivariate analysis (Table 3), whereby, in
nivariate analysis, PPM (i.e., indexed EOA) accounts for
1% of the variance of PA pressure compared to 28% for
ompliance, whereas, in multivariate analysis, the indepen-
ent contribution of PPM remains at 41%, but that of
ompliance decreases to 10%, suggesting that compliance is
ndeed influenced by PPM. Also consistent with this
bservation is the fact that reduced atrioventricular compli-
nce had a minimal effect on PA pressure in the absence of
PM, whereas the combination of PPM and low atrioven-
ricular compliance was associated with a dramatic increase
n the prevalence of PA hypertension (Fig. 4). Hence, it
ould appear that a decrease in atrial compliance may be
elatively well tolerated in patients with a prosthetic valve
ith a large EOA and no PPM but that the same condition
ay be much less well tolerated in patients with a relative
bstruction to flow due to the prosthesis.
linical implication. The clinical implications of these
esults are important given that PPM is frequent in patients
ndergoing MVR. Moreover, as opposed to most other risk
actors for PA hypertension, PPM may eventually be
voided by using a prospective strategy at the time of
peration. Such a strategy has been well described and
alidated for the prevention of PPM in the aortic position
40,43,46,47). Suggested options to avoid PPM in the aortic
osition are either to perform an aortic root enlargement to
ccommodate a larger prosthesis or to use another type of
rosthesis with a better hemodynamic profile (i.e., with a
arger EOA; e.g., a stentless bioprosthesis or a mechanical
alve).
In the mitral position, there is no alternative technique
llowing implantation of a larger prosthesis size. The
reventive strategy should, therefore, be focused on the
mplantation of the prosthesis having the largest EOA for a
iven size. The objective would be to obtain a postoperative
ndexed EOA 1.2 to 1.3 cm2/m2. To this effect, the
ileaflet mechanical valves of new generation may be an
nteresting option given that their hemodynamics are gen-
rally superior to that of other prostheses (48).
tudy limitations. The main limitation of this study is its
etrospective design. This may have introduced some selec-
ion bias. Also, the preoperative values of systolic PA
ressure could not be obtained in several patients. Further
rospective studies are, thus, necessary to determine the
mpact of PPM on the regression or progression of PA
ypertension.
Beyond PPM and atrioventricular compliance, otheractors, such as pulmonary vascular resistance or PA com-
liance, may also influence the normalization of PA pres-
ure after MVR. However, these factors are difficult to
stimate by Doppler-echocardiography, and they were in-
eed not measured in this study. Nonetheless, it should also
e considered that, as opposed to PPM, these factors are
ardly preventable or modifiable. Hence, although this
nformation could be used to evaluate postoperative out-
ome, it could not contribute to the development of a
rospective strategy that would optimize the regression of
A hypertension after MVR.
onclusions. Persistent PA hypertension is frequent after
VR and strongly associated with the presence of valve
PM. The clinical implications of these findings are impor-
ant given that PPM may be avoided by using a simple
rospective strategy at the time of operation.
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